Printer Friendly

COMPANY SUBMITS 510(k) APPLICATION TO FDA FOR PHENCYCLIDINE ASSAY

 RANCHO CUCAMONGA, Calif., Nov. 22 /PRNewswire/ -- U.S. Drug Testing, Inc. (PSE: USD.P) announced today that it has submitted a 510(k) application to the FDA for its assay that detects phencyclidine (PCP) utilizing the Flow Immunosensor Technology.
 The Company believes that its recently completed performance evaluation studies of the PCP assay involving urine substantiate the claims made in its FDA filing, which establishes equivalency to existing approved devices.
 The Company previously received marketing approval from the FDA of the 510(k) application for its Flow Immunoassay System Model 9000. Marketing approval has also been granted for the assay which detects cocaine and its metabolite benzoylecogine, as well as for the assay which detects opiates, including heroin and morphine. The Company will begin marketing after it has received FDA marketing approval of further assays including the already submitted amphetamine assay. Submission to the FDA of the remaining assay, marijuana, is expected by year end.
 The Flow Immunosensor technology provides a more sensitive method of testing for drugs of abuse while significantly decreasing the assay time and cost. This technology, developed by scientists at the Naval Research Laboratory, was licensed to the Company in January 1992 from the United States Government through the Technology Transfer Act.
 U.S. Drug Testing, Inc. is a 67 percent owned subsidiary of U.S. Alcohol Testing of America, Inc. (AMEX: AAA) and is engaged in the research and development of devices which detect drugs of abuse from urine and saliva samples.
 -0- 11/22/93
 /CONTACT: Gary S. Wolff of U.S. Drug Testing, Inc., 909-466-8378/
 (USD AAA)


CO: U.S. Drug Testing, Inc. ST: California IN: HEA SU: PDT

GK -- NY011 -- 6705 11/22/93 09:21 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 22, 1993
Words:285
Previous Article:ALAMAR BIOSCIENCES ANNOUNCES MAJOR INTERNATIONAL ALLIANCE; AGREEMENT EXPANDS WORLDWIDE MARKETS AND R&D OPPORTUNITIES
Next Article:NEWBRIDGE LEAPS INTO NUMBER 1 SLOT IN WORLDWIDE T1/E1 MULTIPLEXER MARKET
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters